Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (321-330 of 418) with videos related to

Pageof 42
Sort By:
Cancer Research Communications|June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE StudyRahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type FibromatosisNicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, et al.
Cancer Medicine|June 30, 2018
Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide studyEmmanuelle Bompas, Loïc Campion, Antoine Italiano, et al.
JHEP Reports : Innovation in Hepatology|October 13, 2025
Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomesThomas Pudlarz, Anthony Turpin, Natalia Soledad Tissera, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose EscalationCapucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
BMC Cancer|June 10, 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsAnne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Pageof 42

Showing results (321-330 of 418) with videos related to

Sort By:
Pageof 42
Cancer Research Communications|June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE StudyRahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type FibromatosisNicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, et al.
Cancer Medicine|June 30, 2018
Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide studyEmmanuelle Bompas, Loïc Campion, Antoine Italiano, et al.
JHEP Reports : Innovation in Hepatology|October 13, 2025
Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomesThomas Pudlarz, Anthony Turpin, Natalia Soledad Tissera, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose EscalationCapucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
BMC Cancer|June 10, 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsAnne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Pageof 42